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ABSTRACT
Experimental allergic encephalomyelitis (EAE) is considered as the murine model of multiple
sclerosis. Daidzein a phytostrogenic compound of soy is known to impose immunomodulatory and
antioxidative effects. We conducted this study to assess the potential protective and therapeutic
effects of daidzein on allergic encephalomyelitis.
C57BL/6 mice were induced with allergic encephalomyelitis using myelin oligodendrocyte
glycoprotein (35­55) and received daidzein or dimethyl sulfoxide as the vehicle control. To assess
the protective effect of daidzein, the mice were administered with 20 mg/kg of daidzein from 21
days prior to 21 days post EAE induction on a daily basis. To evaluate the therapeutic effect of
daidzein, mice were fed with 300 mg/kg daidzein after the appearance of the first clinical signs for
10 days. One day after the last gavage, the mice were sacrificed. Spleen and brain were removed for
further histological and immunological analysis.
Feeding mice with low dose of daidzein prior to disease induction did not affect disease severity.
However, treating with high dose of daidzein after the onset of the disease reduced interferon­γ and
interleukin­12 secretion, enhanced interleukin­10 production, suppressed lymphocyte proliferation,
and decreased cytotoxicity as judged by lactate dehydrogenase release.
In conclusion, daidzein reduced the extent of demyelination and disease severity. Chronic oral
therapy with low dose of daidzein did not prevent experimental autoimmune encephalomyelitis.
However, high doses of daidzein could prohibit disease exacerbation.
Keywords: Daidzein; Experimental allergic encephalomyelitis (EAE); Immunomodulation;
Interferon­gamma; Isoflavones; Multiple sclerosis; Soy
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INTRODUCTION 
Multiple sclerosis (MS) is an immune-mediated
inflammatory disease of the central nervous system
(CNS) that can lead to irreversible clinical disability in
most severe cases. 1 Most of the current approved
therapies possess some disadvantages that can cause
non-adherence to treatment including administration via
injection, costs, partial effect, and potential toxicity.2 
Moreover, although current therapies are effective at
decreasing the frequency and severity of relapses, they
have little impact on progressive forms of the disease.
Experimental allergic encephalomyelitis (EAE) is a T-
cell mediated autoimmune disease, validated as the
animal model of MS.3 Both CD4+ and CD8+ T-cells
were reported to be important in the development of
EAE.4 In EAE many T helper (Th)1-type cytokines
(proinflammatory) contribute to the process of
demyelination, while several Th2-type cytokines have
been implicated in remyelination and survival of
5 neurons. 
Daidzein is one of the most potent isoflavones of soy
bean. Soy bean is known as the main dietary source
of isoflavones and has been traditionally consumed
in Far East countries.6 Isoflavones, as a group of
phytoestrogens, appeared to possess weak estrogenic
and/or antiestrogenic actions.7 Considering the
immunomodulatory actions of estrogen, it may be
probable that daidzein also influence the immune
system. A study, treating ovariectomized balb/c mice
with daidzein resulted in a reduction of splenic CD4+ T
cells and tumor necrosis factor-alpha (TNF-α)
secretion.8 Daidzein was also reported to suppress
Interferon­gamma (IFN-γ) production in splenocytes
isolated from C57BL/6 mice.9 Treating mice with 20
mg/kg of daidzein was also reported to reduce plasma
levels of Interleukine (IL)-6 and TNF-α in an animal
model of rheumatoid arthritis.10 In addition daidzein
is known to possess antioxidative properties.11 
Moreover, intraperitoneal injection of 200 mg/kg of
genistein, another soy isoflavone, to EAE-induced
C57BL/6 mice has recently been reported to modify
Th1/Th2 balance and reduce rolling and adhering
12,13 of leukocytes. Regarding the structural similarity
of genistein and daidzein and the immunomodulatory
and antioxidative roles of daidzein, we conducted this
study to investigate potential protective and therapeutic
effects of oral daidzein on the progressive model of
EAE.
MATERIALS AND METHODS 
Mice
The study was performed on 10-12 week old female
C57BL/6 mice (Pasture institute, Iran). The animals
were housed with free access to food and water on a 12
hour light-dark cycle. All protocols used in this
experiment were approved by the Tehran University of
Medical Sciences committee on laboratory animals. The
mice were assigned into four groups, two groups in each
set of experiments. In the first set of the experiment, the
protective effect of oral daidzein was studied. In second
set, the therapeutic effect of daidzein was the subject of
the study.
Daidzein Administration 
To assess the protective effect of daidzein, the mice
(n=6/group) were: 1) administered with 20 mg/kg
daidzein dissolved in 0.1 ml of Dimethyl sulfoxide
(DMSO, Sigma Aldrich, USA) (11%) (daidzein­
protection), 2) gavaged with 0.1 ml DMSO 11% as the
vehicle control (n= 6/group) (control-protection). Oral
gavage began 21 days before immunization and
continued up to 21 days after immunization on daily
bases (43 days including day 0). Twenty mg/kg of
daidzein has been reported to have immunomodulatory
effects in collagen induced arthritis (CIA) and
consequently protect rats against this autoimmune
disease.10 As CIA and EAE have similar pathology, we
adopted this dose for assessing the protective potency of
daidzein.
To study the therapeutic effect of daidzein, the mice
were induced with EAE. After the appearance of the
first clinical sign (score=1), the mice were administered
with 1) 300 mg/kg daidzein dissolved in 0.1 ml DMSO
11% (daidzein-therapy), or 2) 0.1 ml DMSO as vehicle
control (control-therapy). As the bioavailability of oral
daidzein is about 50%, for assessing the therapeutic
effect of daidzein, we administered mice with 300
mg/kg of daidzein.14 
EAE Induction 
The mice were immunized with a 1:1 ratio of myelin
oligodendrocyte glycoprotein (MOG) 35-55 (Alexis,
Switzerland) dissolved in Phosphate buffered saline
(PBS) (300 µg MOG in 100 µL PBS) and complete
Freund’s adjuvant (CFA) (100 µL) containing 0.4 mg of
mycobacterium tuberculosis (Sigma-Aldrich, USA). In
the first set of the experiments, after 21 days of gavage,
257/ Iran J Allergy Asthma Immunol, Summer 2014 Vol. 13, No. 4, August 2014
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200 µL/ mouse MOG-CFA emulsion was
subcutaneously administered on the four sites of
the upper flanks (day 0). The additional immune
adjuvant, pertussis toxin (PTX) (Sigma-Aldrich, USA)
in 10% PBS was intraperitoneally injected (500
ng/mouse) on the initial day of immunization and again
48 hours later. In the second set of the experiments,
after a week of adaptation, the EAE was induced in mice
by protocol.
Clinical Evaluation of EAE 
The following grading scheme was u
score the animals: 0, for no clinical sign
1, flaccid/floppy tail, 2, walking deficit
hind limb paralysis 3, bilateral hind lim
paraplegia with forelimb weakness, 4, 
5, for moribund.  
In the first set of the experiments, th
were assessed daily for 21 days post i
the second set of the experiments, clini
assessed daily up to 10 days after the ap
first clinical sign.  
 
Histological Assessments 
Twenty-four hours after the last trea
were sacrificed. Brain of the animals w
post-fixed in 10% paraformaldehyde an
for 48 hours. Prior to sectioning, the tis
PBS 10% for 24 h and imbedded in par
sections (8 microns) were cut on th
stained. For assessing the percentage o
luxol fast blue- LFB (Merck, Germa
violet (BDH, England) staining 
Demyelination was assessed in at leas
each mouse. 
 
Spleen Cytokine Assessment   
sed to clinically
s, 0.5, hook tail,
s, 2.5, unilateral
b paralysis, 3.5,
quadriplegia and
e clinical scores
mmunization. In
cal scores were
pearance of the
tment, the mice
ere removed and
d stored at 4O C
sues were put in
affin. The brain
e cryostat and
f demyelination
ny)/ Cresyl fast
was used.
t 5 sections for
The mice were sacrificed 24 hours after the last
gavage and their splenocytes were isolated.
Mononuclear cells obtained from spleens of the
immunized mice were prepared and incubated with 1.5
ml in RPMI-1640 medium at a concentration of 2×106 
cells/well in 24-well plate (Nunc, Denmark) for two
days. The RPMI was supplemented with 10% FCS, 1%
L-glutamine, 1% HEPES, 0.1% 2ME, and 0.1%
penicillin/streptomycin, and pulsed with 10µg/ml
daidzein. The cell supernatants were collected. The
amount of cytokines (INF-γ, IL-10 and IL-12) in cell
supernatants was assessed using sandwich-based ELISA
kits (ELISA Ready-SET-Go, eBioscience, USA). The
tests were performed according to the manufacturer’s
protocol. All tests were performed in triplicate for each
mouse.
Brain Cytokine Assessment 
The concentration of brain cytokines (INF-γ, IL-10
and IL-12) was assessed 24 hours after the last gavage.
For this purpose, 100 mg of the brain tissue of each
mouse was dissolved in 10 ml of extracting solution
consisting of 50 µM tris (Sigma-Aldrich, USA), 2 mM
EDTA (Merck, Germany), 0.1 M NaCl (Sigma-Aldrich,
USA), 1 mM dithiotheritol (Merck, Germany), and 200
µM phenylmethylsulfonyl fluid (Merck, Germany), 1
µg/ml chymostatin (Sigma-Aldrich, USA), and 1 µg/ml
trypsin inhibitor (Sigma-Aldrich, USA) (15) . Brain
homogenate was spun at 4oC for 10 minutes at 10000 g.
Level of INF-γ, IL-12 and IL-10 were determined in
brain supernatant using sandwich-base ELISA kit
(eBioscience, USA) following the manufacturer’s
instruction. All tests were performed in triplicate for
each mouse.
Lymphocyte Proliferation Assay (LPA) 
Twenty four hours after the last oral administration,
single cell suspension of mononuclear cells
was obtained from the immunized mice and used
for lymphocyte proliferation assay. Briefly, the
suspension of isolated spleen cells was treated with
lysis buffer [0.15 M NH4Cl, 1 mM KHCO3, 0.1
mM Na2EDTA, (pH 7.2)]. In 96-well flat-bottom
culture plates (Nunc, Denmark), 2x105 cells/ well
were cultured. The preparations were cultured with
RPMI-1640 medium supplemented with 10% fetal
calf serum, 1% L-glutamine, 1% HEPES, 0.1% 2ME,
0.1% penicillin/streptomycin and incubated in the
presence of 10 µg/ml daidzein. T cell mitogen
phytohemagglutinin-PHA (Sigma chemicals, Australia)
at a concentration of 5 µg/ml was used as the positive
control. After 3 days, MTT (3-(4, 5-Dimethylthiazol-2­
yl)-2,5-Diphenyltetrazolium Bromide) (Sigma
chemicals, Australia) was added per well in
concentration of 5 µg/ml and was incubated for 5 hours
at 37 ºC in 5% CO2. DMSO (100 µl) was added to
dissolve the produced formazan crystals.
The plates were read at 540 nm, and the results were
expressed as stimulation index (SI). The SI was
determined as follows: OD values of stimulated cells
(Cs) minus relative cell numbers of unstimulated cells
Vol. 13, No. 4, August 2014 Iran J Allergy Asthma Immunol, Summer 2014/ 258
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(Cu) by relative OD values of unstimulated cells. % Cytotoxicity =
SI = (Cs _ Cu)/Cu
All tests were performed in triplicate for each
16 
mouse.­
Cell Cytotoxicity Assay 
Twenty-four hours after the final administration, the
mice were sacrificed and their splenocytes were isolated.
For each sample obtained from an individual mouse,
single cell suspension of mononuclear cells (used as the
effecter cells) was co-cultured in RPMI 1640 medium
with washed target cells, EL4 at various effector-to­
target cell for 4 h in phenol red-free RPMI 1640
containing 3% FCS. For preparation of the target cells,
EL-4 cells were stimulated with daidzein antigen.
After centrifugation, the supernatants (50 µl/ well)
were transferred to the 96-well flat-bottom plates, and
lyses of the target cells were determined by measuring
Lactate dehydrogenase (LDH) release using
Cytotoxicity Detection Kit (LDH) according to the
procedures stated by the manufacturer (Takara
Company, Japan). Several controls were used for the
cytotoxicity assay.
“High control” was the total LDH released from the
target cells, and all EL4 cells were lysed by a medium
containing 1% Triton X-100. “Low control” was the
natural release of LDH from the target cells, which was
obtained by adding EL4 cells only in the assay medium.
“T-cell control” was used to measure the natural release
of LDH from T cells obtained by adding different ratios
of T cells only in the assay medium. The assay was
performed in triplicates for all samples, including the
controls.
The LDH-mediated conversion of the tetrazolium
salt into red formazan product was measured at 490 nm
after incubation at room temperature for 30 min. The
percentage of specific cytolysis was determined by the
following formula:
[(experimental value - effector cell control) 
- low control⁄high control - low control] x 100
Statistical Analysis 
The data were analyzed with SPSS 17. One-way
analysis of variances (ANOVA) was used to compare
clinical and histological signs of the disease, as well as,
cytokine concentrations between the studied groups.
Sheff’s honesty significant intergroup comparison at the
0.05 level of significance was adopted for all
comparisons.
RESULTS 
Clinical Assay
In the first set of the experiments, daidzein
administration (20 mg/kg) did not prevent mice from
EAE. The low dose of daidzein did not significantly
affect the day of onset, mean daily, commutative, or
maximum clinical score (Figure 1).
In the second set of the experiments, the mice were
gavaged with dadizein or DMSO up to 10 days after the
appearance of the first clinical sign. 9 to 14 days
following immunization, mice developed clinical signs
of EAE. No significant differences in the mean onset
time were observed between the two groups. The mean
daily clinical score of the daidzein-treated group was
always lower than the controls; the differences became
significant on days 17, 18, and 19. Daidzein also
significantly reduced cumulative and maximum disease
score (Figure 1 and Table 2).
In the first set of the experiments, demyelinated
lesions were scattered widely throughout the brain in
DMSO-treated mice. The daidzein-treated mice did not
show milder CNS pathology compared to controls. In
the second set of the experiments, demyelination was
notably absent in the daidzein treated mice (Figure 2).
Table 1: Effect of oral administration of daidzein or DMSO on clinical signs of experimental allergic encephalomyelitis (EAE)
Incidence‡ Onset (day) Commutative Maximum clinical score
disease score
Protection Control 6/6 11.33±1.5 25.25±7.99 3±0.45
Daidzein 5/6 11.25±0.51 22.25±3.88 2.87±0.62
Therapy Control 5/6 11±1.67 23.25±5.33 2.91±0.37
Daidzein 6/6 11.2±1.6 12.5±5.67* 1.6±0.82*
The mega-dose of daidzein (300 mg/kg) decreased commutative and maximum disease score significantly. All data is represented as
mean± SD. ‡ratio, *P<0.05 compared to control-therapy
259/ Iran J Allergy Asthma Immunol, Summer 2014 Vol. 13, No. 4, August 2014
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Figure 1. Effects of oral administration of daidzein on the mean daily clinical scores of experimental allergic
 

encephalomyelitis (EAE). Administering with 20 mg/kg (n=6) from 21 days prior to 21 days post immunization did not reduce
 

the severity of clinical signs compared to the vehicle controls. Gavaging with daidzein after the onset of clinical signs for 10
 

days reduced the mean daily clinical score. The difference became significant (p<0.05) from day 17 to 19 compared to control
 

group.. All data is represented as mean± SD.
 

49 μm46.1 μm
A-1 A-2
 

47 μm
62 μm
B-1 B-2
 

Figure 2. Demyelination of the brain. A, brain sections of control-protection (A-1), daidzein-protection (A-2), control-therapy
 

(B-1), and daidzein-therapy (B-2) groups are stained using luxol fast blue & Cresyl fast violet. 20 mg/kg of daidzein was used
 

as a protective dose from 21 days prior to 21 days post induction. 300 mg/kg of daidzein was used as a therapeutic dose for 10
 

days after disease onset. Therapeutic dose of daidzein reduced the extent of demyelination.
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Immunological Assay  
Cytokine Profile
The animals were sacrificed 24 hours after the last
treatment. In the first set of the experiments, brains and
spleens of the animals were dissected. In splenocytes
isolated from daidzein-treated animals after daidzein
exposure, no significant differences were detected in
levels of IFN-γ, IL-12, and IL-10. The comparable effect
was noted on brain cytokine profile (Figure 3).
As presented in figure 3, in the second set of
the experiments, in the splenocytes removed from
daidzein-treated group, after daidzein exposure, IFN-γ
and IL-12 levels were significantly down regulated
compared to vehicle-control (p=0.02 and 0.002,
respectively). Daidzein also reduced IFN-γ (p=0.024)
secretion in brain. It enhanced IL-10 secretion in
brain and splenocytes (p= 0.014 and 0.001,
respectively).
** ** 
* 
** 
†
* 
†
Figure 3. The effect of daidzein on cytokine profile (IFN-γ, IL-10 and IL-12) of spleen and brain. To assess the protective role
of daidzein, the mice either received daidzein (20 mg/kg) or DMSO as the vehicle control from 21 days before to 21 days after
immunization. To evaluate the therapeutic effect of daidzein, mice were either gavaged with daidzein (300 mg/kg) or DMSO
after the onset of clinical signs for 10 days. Treating mice with daidzein after the onset of the disease notably reduced IFN-γ
level in brain and splenocytes. It also significantly decreased IL-12 level in splenocyte. Moreover, therapeutic dose of daidzein
enhanced IL-10 secretion in brain and splenocytes. All data are represented as mean± SD. *P<0.05, **P<0.005. †ng/dl
261/ Iran J Allergy Asthma Immunol, Summer 2014 Vol. 13, No. 4, August 2014
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Lymphocyte Proliferation   
Proliferative response of splenocytes’ lymphocytes
was assessed using MTT test. In the first set of
the experiments, in the immunized mice with
daidzein, the proliferative response of lymphocytes
was suppressed, but the difference was not significant
in comparison to the control group. In the second
set of the experiments, the stimulation
index of lymphocytes was reduced significantly (Figure
4).
LDH Cell Cytotoxicity  
Twenty-four hours after the final treatment, single 
ell suspension of mononuclear cells (effecter cells) was 
o-cultured with pulsed EL-4 cells (target cell). 
As shown in Figure 5, in lymphocytes of mice 
hat received the therapeutic dose of daidzein, specific 
ytolytic activity was suppressed at an E/T ratio of 
0:1 significantly as compared to that of DMSO-treated 
nimals (25.2±2.8% v.s. 33.7±1.09%) group. The most 
ignificant differences between all studied groups were 
c
c
t
c
5
a
s
at 50:1 E/T ratios (Figure 5).
*
Figure 4. Lymphocyte proliferation evaluation, using
MTT assay. Lymphocyte proliferation response was
measured in daidzein-treated (20 mg/kg or 300 mg/kg)
mice and compared with DMSO-treated animals. In mice
treated with the therapeutic dose of daidzein, lymphocyte
proliferation response was significantly lower, in
comparison to the DMSO group. All data are expressed as
mean± SD. *P<0.05.
Figure 5. Cell cytotoxicity assays in mice treated with
daidzein using LDH release assay. After oral treatment
with DMSO or daidzein (20 mg/kg from 21 days before
EAE induction or 300 mg/kg after disease onset), the
spleens were harvested as described in materials and
methods. The data were collected from LDH results at
various E/T ratios (E/T=25:1, 50:1, 100:1) and expressed as
cytotoxicity percentage ± SD. The data shown here are
from three independent experiments with triplicates. The
percent of cytotoxicity was significantly lower in the
daidzein-treated group compared to vehicle-control.
*P<0.05 compared to control.
DISCUSSION 
Few evidences exist on the immunomodulatory
effect of daidzein. Up to the best of our knowledge, no
study has previously been performed on the effect of
daidzein on EAE. We found that administrating mice
with high doses of daidzein after the onset of the disease
can attenuate EAE severity. However, gavaging with a
low dose of daidzein prior to EAE-induction does not
provide protection against disease induction.
The therapeutic dose of daidzein reduced the
stimulation index of lymphocytes which mainly
represents memory CD4+ T-cell proliferation. High dose
of daidzein also decreased the percent of cytotoxicity
which mainly manifested CD8+ activity. EAE is mainly
characterized by infiltration of myelin-auto reactive
CD4+ and CD8+ T cells into the CNS.16 We also
showed that gavaging with high dose of oral daidzein
resulted in suppression of IFN-γ and IL-12 production,
as well as the enhancement of IL-10 secretion. IFN-γ
also controls the differentiation of CD4+ cells into Th1
effectors as well as, initiating the production of pro-
inflammatory cytokines.17 IFN-γ was found to be
Vol. 13, No. 4, August 2014 Iran J Allergy Asthma Immunol, Summer 2014/ 262
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increased in the CSF and CNS of patients with MS and
IFN-γ administration to MS patients exacerbates the
disease.18 IL-10 is an anti-inflammatory cytokine that is
produced by macrophages, monocytes, B cells and Th2
cells. It inhibits the production of pro-inflammatory
Cytokines (IL-1 and TNF-α) by macrophages.19 In EAE
models, mice with IL-10 deficiency developed more
severe EAE compared to the controls and even to IL-4
deficient mice, suggesting IL-10 has a unique role that
cannot be substituted by other Th2 cytokines.20 
Treatment with IL-10 has also been shown to protect
against EAE progression in mice.20 
In agreement with our results, a previous in vitro
study reported that high doses of daidzein (50 µm)
reduced IFN-γ production and lymphocyte proliferation
of concanavalin A-stimulated splenocytes.21 Also, Tyagi
AM. et al. reported that gavaging ovariectomized Balb/c
mice with daidzein reversed the ovariectomy induced
CD4+ T cell expression in spleen.8 As mentioned
previously, De paula et al. reported that intraperitoneal
administration of 200 mg/kg genistein, after the onset of
disease, reduced EAE severity by reducing IFN-γ and
IL-12 production, decreasing the rolling and adhering of
leukocytes on brain microvasculature, as well as
enhancing IL-10 secretion.12 Our results showed that
similar to genistein, therapeutic dose of daidzein can
attenuate EAE severity.
Few in vivo studies were performed on the
immunomodulatory effects of daidzein. One of the best
examples was a study on CIA. Mohammad-Shahi et al.
reported that treating CIA-induced Spraugue-Dawley
rats with 20 mg/kg daidzein postponed disease onset and
10	 	 -8reduced its severity. Also in an in vitro study, 10 M
daidzein reduced IFN-γ production in splenocytes
isolated from C57BL-6 mice.9 In contrast to
Mohammad-shahi results and the previous in vitro
study, in our study low-dose daidzein did not show the
predicted protective effect on EAE. The observed
difference with the previous in vivo study may be due to
the difference in the pathological feature of EAE and
CIA. They reported that the low dose of daidzein protect
rats against CIA by reducing the serum concentration of
TNF-α, IL-6, and leptin. Ideas on the role of IL-6 in
EAE are controversial. IL-6 signaling has been
identified as a stimulant that directs cells toward Th17.
In a number of recent studies, Th17 (IL-17A-secreting-
Th cells) was considered essential in developing EAE.
On the other hand, in another study greatly increased
levels of T cell-derived IL-17A expression was reported
to have no effect on the development of EAE and the
quality and quantity of CNS inflammation.22 TNF-α was
also playing a dual role during EAE. The complete
elimination of TNF-α may induce disease severity.
However, incomplete modulation of TNF-α expression
may provide protection against EAE.23 So reducing IL-6
and TNF-α level might not necessarily induce tolerance
to EAE. A major difference between our in vivo animal
study and the previous in vitro study was the
bioavailability of daidzein that could have been
significantly influenced the results. Furthermore,
physiological and pathological factors in autoimmune
disease including other immune cells may play a role in
predicting lymphocyte potentiation and cytokine action.
To mention our limitations, we did not evaluate the
activity of CD4+ and CD8+ T cells with more elaborate
methods. However, we cannot rule out daidzein effect
on CD4+ and CD8+ T cells measured by MTT and LDH
tests. Further studies on protective and therapeutic
effects of different doses of daidzein are warranted.
In conclusion, Oral administration of low dose of
daidzein did not prevent EAE progression. However,
treating with high dose of daidzein at the onset of
clinical signs modulated T-cell response and
consequently alleviated disease symptoms.
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